Select publications

Preoperative (neoadjuvant) systemic therapy

The effect on primary tumor response of adding sequential Taxotere to Adriamycin and cyclophosphamide: Preliminary results from NSABP protocol B-27. Breast Cancer Res Treat 2001;Abstract 5.

Aapro MS. Neoadjuvant therapy in breast cancer: Can we define its role? Oncologist 2001;6 Suppl 3:36-9. Abstract

Anderson TJ et al. Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer. Br J Cancer 2002;87(3):334-8. Abstract

Chollet P et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 2002;86(7):1041-6. Abstract

Cleator S et al. The biology of neoadjuvant chemotherapy for breast cancer. Endocr Relat Cancer 2002;9(3):183-95. Abstract

Dixon JM et al. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: A randomized, double-blind, single-center study. Clin Cancer Res 2000;6(6):2229-35. Abstract

Ellis MJ et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a Phase III randomized trial. J Clin Oncol 2001;19(18):3808-16. Abstract

Geisler J et al. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res 2001;7(5):1230- 6. Abstract

Green M, Hortobagyi GN. Neoadjuvant chemotherapy for operable breast cancer. Oncology (Huntingt) 2002;16(7):871-84, 889; discussion 889-90, 892-4, 897-8. Abstract

Heys SD et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 2002;3 Suppl 2:S69-74. Abstract

Mamounas EP, Fisher B. Preoperative (neoadjuvant) chemotherapy in patients with breast cancer. Semin Oncol 2001;28(4):389-99. Abstract

Milla-Santos A et al. Anastrozole (A) as neoadjuvant (NEO) therapy for hormone-dependent locally advanced breast cancer (LABC) in postmenopausal (PM) patients (pts). Breast Cancer Res Treat 2001;Abstract 302.

Newman LA et al. A prospective trial of preoperative chemotherapy in resectable breast cancer: Predictors of breast-conservation therapy feasibility. Ann Surg Oncol 2002;9(3):228-34. Abstract

Smith IC et al. Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel. J Clin Oncol 2002;20(6):1456-66. Abstract

Smith IC, Miller ID. Issues involved in research into the neoadjuvant treatment of breast cancer. Anticancer Drugs 2001;12 Suppl 1:S25-9. Abstract

van der Hage JA et al. Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001;19(22):4224-37. Abstract

von Minckwitz G et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: A randomized, controlled, open Phase IIb study. J Clin Oncol 2001;19(15):3506-15. Abstract

Wolmark N et al. Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;(30):96-102. Abstract

Breast cancer chemoprevention

Chlebowski RT. Breast cancer risk reduction: Strategies for women at increased risk. Annu Rev Med 2002;53:519-40. Abstract

Chlebowski RT et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 2002;20(15):3328-43. Abstract

Chlebowski RT et al. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: Tamoxifen and raloxifene. J Clin Oncol 1999;17(6):1939-55. Abstract

Fisher B et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90(18):1371-88. Abstract

Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 2001;19(3):881-94. Abstract

IBIS Investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): A randomised prevention trial. Lancet 2002;360(9336):817-24. Abstract

O’Reagan RM, Jordan VC. Tamoxifen to raloxifene and beyond. Semin Oncol 2001;28(3):260-73. Abstract

Tan-Chiu E et al. Effects of tamoxifen on benign breast disease in women at high risk for breast cancer. J Natl Cancer Inst 2003;95(4):302-7. Abstract

Vogel VG. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts. Clin Cancer Res 2001;7(12Suppl):4413s-8s;discussion 4411s-2s. Abstract

Wickerham DL, Tan-Chiu E. Breast cancer chemoprevention: Current status and future directions. Semin Oncol 2001;28:253-9. Abstract

Home · Search